Limits...
Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid.

Flanagan S, Fang E, Muñoz KA, Minassian SL, Prokocimer PG - Pharmacotherapy (2014)

Bottom Line: Treatment-related adverse events occurred in 41% of subjects.Most adverse events were related to infusion site and became more frequent with multiple dosing.These results from a population of healthy volunteers support once/day dosing of tedizolid phosphate 200 mg with both the oral and IV formulations, without the need for dose adjustment when switching administration routes.

View Article: PubMed Central - PubMed

Affiliation: Cubist, San Diego, California.

Show MeSH

Related in: MedlinePlus

Study design. IV = intravenous.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4260119&req=5

fig01: Study design. IV = intravenous.

Mentions: The study was conducted in four sequential phases: two studies that assessed the PK of IV tedizolid phosphate at doses ranging from 100–400 mg/day (i.e., a single-ascending dose study followed by a multiple-dose study), an absolute bioavailability study, and a venous tolerability study (Figure1).


Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid.

Flanagan S, Fang E, Muñoz KA, Minassian SL, Prokocimer PG - Pharmacotherapy (2014)

Study design. IV = intravenous.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4260119&req=5

fig01: Study design. IV = intravenous.
Mentions: The study was conducted in four sequential phases: two studies that assessed the PK of IV tedizolid phosphate at doses ranging from 100–400 mg/day (i.e., a single-ascending dose study followed by a multiple-dose study), an absolute bioavailability study, and a venous tolerability study (Figure1).

Bottom Line: Treatment-related adverse events occurred in 41% of subjects.Most adverse events were related to infusion site and became more frequent with multiple dosing.These results from a population of healthy volunteers support once/day dosing of tedizolid phosphate 200 mg with both the oral and IV formulations, without the need for dose adjustment when switching administration routes.

View Article: PubMed Central - PubMed

Affiliation: Cubist, San Diego, California.

Show MeSH
Related in: MedlinePlus